These findings support the GLP-1 pathway as an alternative to impaired MC4R, offering a viable treatment
Retrieved from Perkovic, V., Tuttle, K
Given the increasing interest in the potential use of incretins in cardiovascular diseases, conducting randomized controlled trials in this direction is warranted
But since the pharmaceutical company doesnt support that use, it means the provider is taking responsibility for monitoring safety and outcomes. What this means is that you cant just get an official prescription for a microdose of a brand-name GLP-1, says Dr
Tirzepatide (Mounjaro) Tirzepatide is unique because it targets two hormones: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)
PlexusDx's Precision Peptide Genetic Test reveals predispositions in these peptide-signaling pathways, helping providers and patients align expectations and choose appropriate formulations and dosing protocols from the start